Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Tóm tắt
Platinum complexes are clinically used as adjuvant therapy of cancers aiming to induce tumor cell death. Depending on cell type and concentration, cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms. Additionally, cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways. Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression. Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochemical mechanism of action. While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant. Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair. To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers. Thus, understanding of the biochemical mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.
Từ khóa
Tài liệu tham khảo
Frezza, 2010, Novel metals and metal complexes as platforms for cancer therapy, Curr. Pharm. Des., 16, 1813, 10.2174/138161210791209009
Spiro, T.G. (1980). Nucleic Acid-Metal Ion Interactions, John Wiley & Sons, Inc.
Desoize, 2002, Particular aspects of platinum compounds used at present in cancer treatment, Crit. Rev. Oncol. Hematol., 42, 317, 10.1016/S1040-8428(01)00219-0
Che, 2010, Metal complexes in medicine with a focus on enzyme inhibition, Curr. Opin. Chem. Biol., 14, 255, 10.1016/j.cbpa.2009.11.015
Chen, 2009, Metal complexes, their cellular targets and potential for cancer therapy, Curr. Pharm. Des., 15, 777, 10.2174/138161209787582183
Zhang, 2010, Status of bi- and multi-nuclear platinum anticancer drug development, Anticancer Agents Med. Chem., 10, 272, 10.2174/187152010791162270
Lebwohl, 1998, Clinical development of platinum complexes in cancer therapy: An historical perspective and an update, Eur. J. Cancer., 34, 1522, 10.1016/S0959-8049(98)00224-X
Olszewski, 2010, A better platinum-based anticancer drug yet to come?, Anticancer Agents Med. Chem., 10, 293, 10.2174/187152010791162306
Shah, 2009, New-generation platinum agents for solid tumors, Future Oncol., 5, 33, 10.2217/14796694.5.1.33
Florea, 2009, Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity, Neurotoxicology, 30, 194, 10.1016/j.neuro.2008.12.001
Florea, 2006, Metals and metal compounds: Occurrence, use, benefits and toxic cellular effects, Biometals, 19, 419, 10.1007/s10534-005-4451-x
Tsang, 2009, Cisplatin overdose: Toxicities and management, Drug Saf., 32, 1109, 10.2165/11316640-000000000-00000
Knoll, 2006, Hearing genes and cisplatin deafness: A pilot study, Laryngoscope, 116, 72, 10.1097/01.mlg.0000185596.20207.d2
Crul, 2006, Relationship between Cisplatin administration and the development of ototoxicity, J. Clin. Oncol., 24, 918, 10.1200/JCO.2006.10.077
Drottar, 2006, The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs, Laryngoscope, 116, 292, 10.1097/01.mlg.0000197630.85208.36
Momekov, 2006, In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands, Arch. Toxicol., 80, 555, 10.1007/s00204-006-0078-0
Liu, 2006, Pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity, J. Am. Soc. Nephrol., 17, 765, 10.1681/ASN.2005010102
Masubuchi, 2006, Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats, Arch. Toxicol., 80, 347, 10.1007/s00204-006-0079-z
Trevisan, 2004, Erythrocyte aminolevulinic acid dehydratase inhibition by cisplatin, Toxicol. Lett., 152, 105
Keller, 2010, Other drugs acting on nervous system associated with QT-interval prolongation, Curr. Drug Saf., 5, 105, 10.2174/157488610789869256
Pratibha, 2006, Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats, Eur. J. Pharmacol., 532, 290, 10.1016/j.ejphar.2006.01.007
King, 2006, Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects, Clin. Oncol. (R Coll. Radiol.), 18, 38, 10.1016/j.clon.2005.09.001
Garcia, 2005, Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies, Nat. Clin. Pract. Urol., 2, 32, 10.1038/ncpuro0068
Ralph, 2009, Mitochondria as targets for cancer therapy, Mol. Nutr. Food Res., 53, 9, 10.1002/mnfr.200800044
Basu, 2004, Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis-Platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside, Glycoconj. J., 20, 563, 10.1023/B:GLYC.0000043293.46845.07
Brozovic, 2010, The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin, Crit. Rev. Toxicol., 40, 347, 10.3109/10408441003601836
Desoize, 2002, Cancer and metals and metal compounds: Part I—Carcinogenesis, Crit. Rev. Oncol. Hematol., 42, 1, 10.1016/S1040-8428(02)00017-3
Jordan, 2000, Molecular mechanisms involved in cisplatin cytotoxicity, Cell. Mol. Life Sci., 57, 1229, 10.1007/PL00000762
Sedletska, 2005, Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways, Curr. Med. Chem. Anticancer Agents, 5, 251, 10.2174/1568011053765967
Wang, 2004, Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer, Ai Zheng, 23, 865
Chaney, 2005, Recognition and processing of cisplatin- and oxaliplatin-DNA adducts, Crit. Rev. Oncol. Hematol., 53, 3, 10.1016/j.critrevonc.2004.08.008
Schar, 2004, SMC1 coordinates DNA double-strand break repair pathways, Nucl. Acid. Res., 32, 3921, 10.1093/nar/gkh716
Brabec, 2005, Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs, Drug Resist. Updat, 8, 131, 10.1016/j.drup.2005.04.006
Benedetti, 2008, Experimental evidence that a DNA polymerase can incorporate N7-platinated guanines to give platinated DNA, Angew. Chem. Int. Ed., 47, 507, 10.1002/anie.200703160
Coluccia, 2007, Trans-platinum complexes in cancer therapy, Anticancer Agents Med. Chem., 7, 111, 10.2174/187152007779314080
Ruggiero, 2002, Cellular and molecular aspects of drugs of the future: Oxaliplatin, Cell. Mol. Life Sci., 59, 1914, 10.1007/PL00012514
Yeow, 2008, Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway, Cancer Gene Ther., 15, 356, 10.1038/sj.cgt.7701120
Wenger, 2006, Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors, Cell Death Differ., 13, 1740, 10.1038/sj.cdd.4401867
Bellail, 2009, TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges, Rev. Recent Clin. Trials, 4, 34, 10.2174/157488709787047530
Wu, 2004, TRAIL and chemotherapeutic drugs in cancer therapy, Vitam. Horm., 67, 365, 10.1016/S0083-6729(04)67019-1
Hail, 2009, Cancer chemoprevention and mitochondria: Targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state, Mol. Nutr. Food Res., 53, 49, 10.1002/mnfr.200700527
Qian, 2005, Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death, Am. J. Physiol. Cell Physiol., 289, C1466, 10.1152/ajpcell.00265.2005
Muscella, 2008, Pt[(O,O′-acac)(gamma-acac)(DMS)], a new Pt compound exerting fast cytotoxicity inMCF-7 breast cancer cells via the mitochondrial apoptotic pathway, Br. J. Pharmacol., 153, 34, 10.1038/sj.bjp.0707576
Wallace, 2008, Mitochondrial off targets of drug therapy, Trends Pharmacol. Sci., 29, 361, 10.1016/j.tips.2008.04.001
Gogvadze, 2009, Mitochondria as targets for chemotherapy, Apoptosis, 14, 624, 10.1007/s10495-009-0323-0
Bossi, 2006, Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression, Oncogene, 25, 304, 10.1038/sj.onc.1209026
Park, 2006, Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin, Int. J. Oncol., 28, 119
Karger, 2005, Overexpression of protein kinase Cdelta enhances cisplatin-induced cytotoxicity correlated with p53 in gastric cancer cell line, Pathobiology, 72, 152, 10.1159/000084119
Wang, 2006, Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs, Cancer Biol. Ther., 5, 380, 10.4161/cbt.5.4.2477
Pivonkova, 2006, Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain, Biochem. Biophys. Res. Commun., 339, 477, 10.1016/j.bbrc.2005.11.038
Abbosh, 2006, Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells, Cancer Res., 66, 5582, 10.1158/0008-5472.CAN-05-3575
Wang, 2004, Cisplatin-induced post-translational modification of histones H3 and H4, J. Biol. Chem., 279, 20622, 10.1074/jbc.M402547200
Bhatt, 2010, MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival, Mol. Med., 16, 409, 10.2119/molmed.2010.00002
Xie, 2010, miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells, Oncol. Rep., 23, 1693, 10.3892/or_00000813
Splettstoesser, 2007, IP(3) receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis, Br. J. Pharmacol., 151, 1176, 10.1038/sj.bjp.0707335
Tomaszewski, 2007, Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats, Neurotoxicology, 28, 49, 10.1016/j.neuro.2006.07.005
Wang, 2006, Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer, Arch. Otolaryngol. Head Neck Surg., 132, 19, 10.1001/archotol.132.1.19
Maffucci, 2005, Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects, Cancer Res., 65, 8339, 10.1158/0008-5472.CAN-05-0121
Raymond, 2002, Cellular and molecular pharmacology of oxaliplatin, Mol. Cancer Ther., 1, 227
Dieras, 2006, Oxaliplatin and ovarian cancer, Bull. Cancer, 93, S35
Ganjavi, 2006, Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin, Cancer Gene Ther., 13, 415, 10.1038/sj.cgt.7700909
Lacy, 2006, Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV(+) nasopharyngeal carcinoma xenografts in SCID mice, Int. J. Cance, 119, 309, 10.1002/ijc.21804
Basma, 2005, BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53, J. Biomed. Sci., 12, 999, 10.1007/s11373-005-9025-y
Chattopadhyay, 2010, Metal complexes in medicine with a focus on enzyme inhibition, Curr. Opin. Chem. Biol., 14, 255, 10.1016/j.cbpa.2009.11.015
Ohta, 2006, Inhibition of phosphatidylinostitol 3-kinase increases efficacy of cisplatin in vivo ovarian cancer models, Endocrinology, 147, 1761, 10.1210/en.2005-1450
Florea, 2009, Anti-cancer drugs interfere with intracellular calcium signaling, Neurotoxicology, 30, 803, 10.1016/j.neuro.2009.04.014
Florea, A.-M., and Büsselberg, D. (2011). Cisplatin as an anti-tumour drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers, in press.
Torigoe, 2005, Cisplatin resistance and transcription factors, Curr. Med. Chem. Anticancer Agents, 5, 15, 10.2174/1568011053352587
Kartalou, 2001, Mechanisms of resistance to cisplatin, Mutat. Res., 478, 23, 10.1016/S0027-5107(01)00141-5
Righetti, 2006, Molecular alterations of cells resistant to platinum drugs: Role of PKCalpha, Biochim. Biophys. Acta, 1763, 93, 10.1016/j.bbamcr.2005.12.007
Xie, 2006, Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin, Cancer Invest., 24, 1, 10.1080/07357900500449520
Hall, 2008, The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy, Annu. Rev. Pharmacol. Toxicol., 48, 495, 10.1146/annurev.pharmtox.48.080907.180426
Qiu, 2005, Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells, Cancer Detect. Prev., 29, 456, 10.1016/j.cdp.2005.05.004
Pogribny, 2010, Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin, Int. J. Cancer, 127, 1785, 10.1002/ijc.25191
Mohammad, 2006, Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts, Cancer, 106, 1260, 10.1002/cncr.21731
Akiyama, 1999, Mechanisms for resistance to anticancer agents and the reversal of the resistance, Hum. Cell., 12, 95